IDEXX Laboratories Names Jacqueline L. Studer Corporate Vice President and General Counsel

IDEXX Laboratories Names Jacqueline L. Studer Corporate Vice President and General Counsel

WESTBROOK, Maine, September 18, 2014—IDEXX Laboratories, Inc. (NASDAQ: IDXX) announces the appointment of Jacqueline L. Studer as Corporate Vice President, General Counsel and Secretary, effective September 1. Ms. Studer leads the Legal, Compliance, Regulatory Affairs and Quality Assurance groups.

"Jackie comes to us as a proven leader with exceptional experience as a lawyer and business executive. She will be an important leader in supporting IDEXX's growth, and I am pleased to have her assume this role," said Jonathan Ayers, Chairman and Chief Executive Officer.
Prior to joining IDEXX in June of this year, Studer was General Counsel at Blue Health Intelligence, a healthcare data and analytics company. Previously, she served as General Counsel at Allscripts Healthcare Solutions, a publicly traded healthcare IT company, and in several leadership positions at GE Healthcare, a medical technology company, including as General Counsel of the GE Healthcare IT and Performance Solutions division. She has extensive experience in building and leading legal organizations to support high-growth technology companies.

Studer earned a bachelor's degree in management from Purdue and her J.D. at Columbia University School of Law.

About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 5,900 people and offers products to customers in over 175 countries.

Note Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and beliefs, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties, assumptions and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by the Company pursuant to United States securities laws contain discussions of these risks and uncertainties. The Company assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review the Company's filings with the United States Securities and Exchange Commission (which are available from the SEC's EDGAR database at, at various SEC reference facilities in the United States and via the Company's website at

Contact: Ed Garber, Director, Investor Relations, 1-207-556-8155

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…